Search

Background and Aim: Magnetic resonance imaging (MRI) has been widely used as a non-invasive modality to evaluate neurological organ structures. However, brain MRI studies in cats with neurological signs are limited. This study evaluated the association between patient characteristics, neurological signs, and brain lesion locations identified by MRI. Blood profiles of cats with presumptive inflammatory and structural brain lesions were also determined. Materials and Methods: Medical records of 114 cats that underwent brain MRI were retrospectively reviewed. Cats were categorized into five groups based on the location of their lesion: Cerebrum, brainstem, cerebellum, multifocal, and non-structural. Patient characteristics, neurological signs, and hematological profiles were obtained from their medical records. Disease classification was categorized based on their etiologies. Associations were determined using Fisher's exact test. Blood parameters were compared using the Kruskal-Wallis test. Results: A total of 114 cats met the inclusion criteria. Lesions were identified in the cerebrum (21.1%), brainstem (8.8%), cerebellum (6.1%), multifocal (39.5%), and non-structural (24.6%) of the cats. Common neurological signs included seizure activity (56.1%), cerebellar signs (41.2%), and anisocoria (25.4%). The most common brain abnormality was inflammation (40.4%). There was no significant difference in hematological profiles between cats with presumptive inflammatory and non-inflammatory brain lesions. Neutrophils, platelets, total protein, and globulin concentrations were higher in cats with structural brain lesions. Conclusion: The most common neurological signs and brain disease category were seizure activity and inflammation, respectively. However, the hematological profile did not predict inflammatory and structural brain lesions. Further studies with a large number of birds are required to molecularly characterize the circulating strains of this virus in this area.

Dogs suffer from neuropathic pain due to several neurological disorders, particularly intervertebral disc disease. We aimed to identify alternative therapeutics for neuropathic pain relief in dogs by comparing the treatment efficacy of pregabalin and Macleaya extract against neuropathic pain from cervical spinal hyperesthesia caused by intervertebral disc disease in dogs. We evaluated 10 dogs suffering from cervical intervertebral disc disease for neuropathic pain using the filament von Frey aesthesiometer (VFA). The dogs were randomly divided into two groups, G1 (n = 5) was treated with 4 mg/kg of pregabalin/12 hours orally for 14 days, and G2 (n = 5) was treated with 15 mg/kg Macleaya extract once daily orally for 14 days. To detect neuropathic pain, the VFA was used to measure the sensory threshold (ST) on days 0, 7, and 14. The results revealed decreases in all ST outcomes with no significant differences between the groups on day 14 posttreatment, as well as a decrease in the severity of neurological disease in both groups on day 7 posttreatment. No significant differences were detected in hematological and biochemical profiles (alanine aminotransferase (ALT), alkaline phosphatase (ALP), serum creatinine (SCR), urea nitrogen (BUN), and total protein (TP)) in both groups between pre- and posttreatment were not significantly different. The Macleaya extract can reduce neuropathic pain in a similar pattern to pregabalin. Macleaya extract may be effective for the treatment of neuropathic pain in dogs with spinal hyperesthesia.

Hydrocephalus is a neurological disorder characterized by an abnormal accumulation of cerebrospinal fluid (CSF) within the ventricular system of the brain, leading to cerebral ventricular dilation, brain parenchyma compression, and neuronal cell loss. Surgery is an effective method of draining excessive amounts of CSF. Ventriculoperitoneal shunt (VPS) allows excess CSF to divert into the abdomen; this device is the most commonly used in the treatment of hydrocephalus both in veterinary and human patients. This study aims to describe the application of two types of VPS, low-pressure valve and medium-pressure valve, using a frameless stereotactic neuronavigational system in eight severe hydrocephalus in dogs and, in particular, analyze the prevalence of postoperative overshunting. Non-communicating hydrocephalus was found in seven dogs, whereas the rest of them had communicating hydrocephalus caused by traumatic brain injury with a skull fracture. The criteria for pressure valve selection depended on the intraoperative intraventricular pressure (IVP) that was determined by the adaptive manometer, according to the human protocol. Low-pressure valve placement was performed in five dogs, and the others received medium-pressure valve placement. The follow-up period was 2 weeks, 4–12 weeks, and 12 weeks to 12 months. Pre- and postoperative information including neurological signs, CT-Scan or MRI, medical treatment, complications, and ventricular volume were compared in all dogs. Seven dogs showed neurological improvement within 2 weeks after surgery. Overshunting was seen in four dogs who received low-pressure valve placement. Three of them had shunt infections within 4 to 6 weeks after surgery. One dog underwent shunt revision from a low-pressure valve to a medium-pressure valve caused by severe overshunting and progressive neurological signs. In addition, cognitive and learning improvements were evaluated based on the owners’ feedback, and neurological signs were examined during the follow-up period in two dogs that received low-pressure valve placement. We conclude that a medium-pressure valve is recommended for overshunting prevention. However, low-pressure valve placement seems to improve cognitive function and learning ability, which is related to an increase in the brain parenchyma observed during long-term monitoring. Moreover, we also report our experience and surgical procedure for frameless stereotactic ventricular shunt placement (FSVSP) in VPS surgery in dogs affected by hydrocephalus.

Objective: Cellular damage induced by oxidative stress has been involved in the development of neurodegeneration. Curcumin, a dietary polyphenol found in the rhizome of Curcuma longa, has been shown, both in vitro and in vivo, to be an effective reactive oxygen scavenging molecule. We investigated an anti-oxidative effect of curcumin against H2 O2 -induced toxicity in human neuroblastoma cell line SK-N-SH. Methods: The SK-N-SH cells were pre-treated with curcumin 2 hours prior to H2 O2 treatment. We measured cell viability, intracellular reactive oxygen species (ROS) levels, expression of apoptotic-related proteins and caspase-3 activity 24 hours post H2 O2 -induced cytoxicity. Results: Treatment with curcumin at concentrations ranging from 5 to 50 μg/mL was not cytotoxic. Pre-treatment with curcumin at the concentrations of 5 to 50 μg/mL prior to H2 O2 exposure caused a significant decrease in intracellular ROS levels and a significant increase in cell viability in a dose-dependent manner. Expression of activated form of caspase-3 and BAX, a pro-apoptotic protein, measured by Western blotting were reduced when the SK-N- SH cell line was pre-incubated with curcumin. The curcumin pre-treated cells also exhibited less caspase-3 activity. Conclusion: Curcumin has protective effects against H2 O2 -induced toxicity in a dose-dependent manner through its anti-apoptotic and anti-oxidative properties in an in vitro H2 O2 -treated SK-N-SH model.

Alzheimer's disease, a progressive neurodegenerative disease, affects learning and memory resulting from cholinergic dysfunction. Scopolamine has been employed to induce Alzheimer's disease-like pathology in vivo and in vitro through alteration of cholinergic system. N-benzylcinnamide (PT-3), purified from Piper submultinerve, has been shown to exhibit neuroprotective properties against amyloid-β-induced neuronal toxicity in rat cortical primary cell culture and to improve spatial learning and memory of aged rats through alleviating oxidative stress. We proposed a hypothesis that PT3 has a neuroprotective effect against scopolamine-induced cholinergic dysfunction. PT-3 (125–200 nM) pretreatment was performed in human neuroblastoma SH-SY5Y cell line following scopolamine induction. PT-3 (125–200 nM) inhibited scopolamine (2 mM)-induced generation of reactive oxygen species, cellular apoptosis, upregulation of acetylcholinesterase activity, downregulation of choline acetyltransferase level, and activation of p38 and JNK signalling pathways. These findings revealed the underlying mechanisms of scopolamine-induced Alzheimer's disease-like cellular dysfunctions, which provide evidence for developing drugs for the treatment of this debilitating disease.

The identification of a drug that stimulates endogenous myelination and spares axon degeneration during multiple sclerosis (MS) could potentially reduce the rate of disease progression. Using experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, we have previously shown that prophylactic administration of the estrogen receptor (ER) β ligand 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) decreases clinical disease, is neuroprotective, stimulates endogenous myelination, and improves axon conduction without altering peripheral cytokine production or reducing central nervous system (CNS) inflammation. Here, we assessed the effects of therapeutic DPN treatment during peak EAE disease, which represents a more clinically relevant treatment paradigm. In addition, we investigated the mechanism of action of DPN treatment-induced recovery during EAE. Given that prophylactic and therapeutic treatments with DPN during EAE improved remyelination-induced axon conduction, and that ER (α and β) and membrane (m)ERs are present on oligodendrocyte lineage cells, a direct effect of treatment on oligodendrocytes is likely. DPN treatment of EAE animals resulted in phosphorylated ERβ and activated the phosphatidylinositol 3-kinase (PI3K)/serine–threonine-specific protein kinase (Akt)/mammalian target of rapamycin (mTOR) signaling pathway, a pathway required for oligodendrocyte survival and axon myelination. These results, along with our previous studies of prophylactic DPN treatment, make DPN and similar ERβ ligands immediate and favorable therapeutic candidates for demyelinating disease.

To evaluate the localization of functional deficit area in epileptogenic zones of the brain in seven refractory and seven non-refractory epilepsy dogs using technetium 99m labeled with ethyl cysteinate dimer and interictal single photon emission computed tomography [99mTc-ECD SPECT] co-registration with Magnetic Resonance Imaging (MRI). Regions showing perfusion deficits in the SPECT images were analyzed by using the standard semiquantitative evaluation method to compare the level of cortical perfusion to the maximum number of counts within the cerebellum (max C), considered the area of reference. This study showed that SPECT imaging revealed abnormalities in several regions of the brain in both epilepsy groups. The refractory epilepsy dogs showed more frequency area of hypoperfusion in temporal lobe than non-refractory group with not statistically significance (P=0.28). The result suggests the lesion in temporal might be relevance with refractory epilepsy in canine patients. [ABSTRACT FROM AUTHOR]

The current study aimed to assess the effect of using omega-3 concentrate to relieve coxofemoral osteoarthritic pain in dogs. In total, ten dogs with coxofemoral OA were orthopedically evaluated at the coxofemoral joints in order to grade the pain severity. Pain scores were assessed from lameness at walk and trot (1-6), pain on manipulation (1-3), and range of motion (1-4). All dogs orally received omega-3 concentrate (Omacor®, Banner Pharmacaps Europe BV, the Netherlands) for successively four weeks. During the study, they were evaluated for pain scores on a weekly basis. The results revealed that mean body weight of the patients were 27.2±17.3 kg (range 2.8-50.0 kg). As for lameness at walk and trot, pain scores obviously declined within one week of treatment (3.3±0.9 vs 2.0±0.7, p<0.001) and went to 1.7±0.8 at the end of the study. According to joint manipulation, pain scores continuously diminished through the 3rd week (2.5±0.5 vs 1.7±0.7 vs 1.3±0.5, p<0.001) and went to 1.2±0.4 at the end of the study. For range of motion, pain scores decreased progressively during 3 weeks (3.0±0.5 vs 2.3±0.5 vs 1.9±0.3, p<0.001) and went to 1.6±0.5 at the end of the study. In summary, omega-3 concentrate was one of the nouveau alternatives to alleviate painfulness at the coxofemoral joints as obviously seen from continuously declined pain scores, contributing to the better quality of life for the dogs afflicted with coxofemoral OA. [ABSTRACT FROM AUTHOR]